CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer

Yu, Shengnan; Yi, Ming; Xu, Lei; Qin, Shuang; Li, An‐Ping; Wu, Kongming

doi:10.3389/fonc.2019.01515

Cited by 37 publications

(32 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CXCL1 is also known as NAP-3, CINC-1, and GRO-α. This protein was originally identified in melanoma, and it was later confirmed to be expressed in neutrophils, macrophages, and epithelial cells and to be involved in inflammation, angiogenesis, and wound-healing biological processes [ 25 ]. Alzoghaibi et al [ 26 ] found that GRO-α levels were significantly higher in patients with IBD than in healthy controls, and that elevated GRO-α levels exacerbated IBD-related inflammation.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics Analysis of Differentially Expressed Genes and Protein–Protein Interaction Networks Associated with Functional Pathways in Ulcerative Colitis

Cao

Cheng

et al. 2021

Med Sci Monit

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Bioinformatics Analysis of Differentially Expressed Genes and Protein–Protein Interaction Networks Associated with Functional Pathways in Ulcerative Colitis

Cao

Cheng

et al. 2021

Med Sci Monit

View full text Add to dashboard Cite

“…In NSCLC, much attention has been paid to the functions of some CXC chemokines. For example, the CXCL1 paracrine network was identified to be linked with cancer chemoresistance and metastasis in 2012 [18], and in 2020, researchers found that CXCL1 was an unfavorable prognosis factor negatively regulated by DACH1 in NSCLC using immunohistochemistry staining [38]. In 2004, researchers found that COX-2 (cyclooxygenase-2) contributes to the progression of NSCLC tumorigenesis by enhancing the expression of angiogenic chemokines CXCL8 and CXCL5 [39], both of which can contribute to lung cancer progression.…”

Section: Discussionmentioning

confidence: 99%

[Retracted] Bioinformatics Analyses Reveals a Comprehensive Landscape of CXC Chemokine Family Functions in Non‐Small Cell Lung Cancer

Tian

Wang

Liu

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Backgrounds. Lung cancer is a major source of tumor-related death each year with non-small cell lung cancer (NSCLC) being a prevalent subtype. The metastasis from NSCLC to the brain usually imposes many neuron disorders. Previous studies have suggested that communications among cancer cells and interstitial cells are essential in tumorigenesis and are influenced by chemokines. In the tumor microenvironment, CXC chemokines can participate in the shifting of immune cells and manage tumor cell condition, thus affecting the progression of cancer and patient destinies. However, the expression and values of CXC chemokine family in NSCLC have not been systematically illustrated using public databases. Methods. UALCAN, STRING, ONCOMINE, GeneMANIA, cBioPortal, GEPIA, TISIDB, TRRUST, TIMER, Kaplan-Meier Plotter, and R software were utilized in this study. Results. Based on the TIMER and UACLCAN databases, in LUAD patients, the expression levels of CXCL10, CXCL13, and CXCL14 were significantly elevated while the transcriptional levels of CXCL2/3/4/7/12/16 were significantly reduced; in LUSC patients, the expression levels of CXCL6/10/13/14 were significantly elevated while the expression levels of CXCL2/3/4/5/7/11/12/16/17 were significantly reduced. We found remarkable relevance between the pathological stages of LUAD patients and the expressions of CXCL8 (positive) and CXCL17 (negative). Similarly, there are significant correlations between the pathological stages of LUSC patients and the expressions of CXCL1/2/6/17. In LUAD, patients with low expression levels of CXCL1/4/7/8 and patients with high expression levels of CXCL12/14/16 were associated with a significantly better prognosis. But in LUSC, all correlations between chemokines and prognosis are statistically insignificant. Pairwise expression correlation analysis among CXC chemokines shows that there are 7 significant correlations (between CXCL1 and CXCL2, between CXCL1 and CXCL3, between CXCL1 and CXCL8, between CXCL2 and CXCL3, between CXCL4 and CXCL7, between CXCL9 and CXCL10, and between CXCL9 and CXCL11) in LUAD and 4 significant correlations (between CXCL1 and CXCL8, between CXCL2 and CXCL3, between CXCL4 and CXCL7, and between CXCL10 and CXCL11) in LUSC. Significant correlations between the expressions of CXC chemokines and the infiltration of six common types of immune cells were also discovered in both LUAD and LUSC. Conclusions. We provided a comprehensive landscape of the CXC chemokine family in LUAD and LUSC using the bioinformatics method and found differences between LUSC and LUAD in the field of CXC chemokines. Our study may help validate and identify known novel immunotherapeutic targets and prognostic biomarkers.

show abstract

“…Here, consistently with a cancer-promoting role, its systemic concentrations were elevated. Moreover, ADMA levels positively correlated with immune mediators known to support cancer development, the most strongly with GROα (CXCL1), the cytokine released from tumors as well as tumor-associated macrophages and implicated in the recruitment of tumor-associated neutrophils [ 31 ] and promotion of metastasis [ 32 ], respectively, and associated with poor overall survival [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Esophageal Squamous Cell Carcinoma Is Accompanied by Local and Systemic Changes in L-arginine/NO Pathway

Bednarz−Misa

Fortuna

Fleszar

et al. 2020

IJMS

View full text Add to dashboard Cite

The L-arginine/NO pathway holds promise as a source of potential therapy target and biomarker; yet, its status and utility in esophageal squamous cell carcinoma (ESCC) is unclear. We aimed at quantifying pathway metabolites in sera from patients with ESCC (n = 61) and benign conditions (n = 62) using LC-QTOF-MS and enzyme expression in esophageal tumors and matched noncancerous samples (n = 40) using real-time PCR with reference to ESCC pathology and circulating immune/inflammatory mediators, quantified using Luminex xMAP technology. ESCC was associated with elevated systemic arginine and asymmetric dimethylarginine. Citrulline decreased and arginine bioavailability increased along with increasing ESCC advancement. Compared to adjacent tissue, tumors overexpressed ODC1, NOS2, PRMT1, and PRMT5 but had downregulated ARG1, ARG2, and DDAH1. Except for markedly higher NOS2 and lower ODC1 in tumors from M1 patients, the pathology-associated changes in enzyme expression were subtle and present also in noncancerous tissue. Both the local enzyme expression level and systemic metabolite concentration were related to circulating inflammatory and immune mediators, particularly those associated with eosinophils and those promoting viability and self-renewal of cancer stem cells. Metabolic reprogramming in ESCC manifests itself by the altered L-arginine/NO pathway. Upregulation of PRMTs in addition to NOS2 and ODC1 and the pathway link with stemness-promoting cytokines warrants further investigation.

show abstract

CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer

Cited by 37 publications

References 65 publications

Bioinformatics Analysis of Differentially Expressed Genes and Protein–Protein Interaction Networks Associated with Functional Pathways in Ulcerative Colitis

Bioinformatics Analysis of Differentially Expressed Genes and Protein–Protein Interaction Networks Associated with Functional Pathways in Ulcerative Colitis

[Retracted] Bioinformatics Analyses Reveals a Comprehensive Landscape of CXC Chemokine Family Functions in Non‐Small Cell Lung Cancer

Esophageal Squamous Cell Carcinoma Is Accompanied by Local and Systemic Changes in L-arginine/NO Pathway

Contact Info

Product

Resources

About